Benchmarking CRISPR-BP34 for point-of-care melioidosis detection in low-income and middle-income countries: a molecular diagnostics study
<p><strong>Background:</strong> Melioidosis is a neglected but often fatal tropical disease. The disease has broad clinical manifestations, which makes diagnosis challenging and time consuming. To improve diagnosis, we aimed to evaluate the performance of the CRISPR-Cas12a...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Elsevier
2024
|
| _version_ | 1797113233658609664 |
|---|---|
| author | Pakdeerat, S Boonklang, P Angchagun, K Chomkatekaew, C Apichaidejudom, N Dokket, Y Faosap, A Wongsuwan, G Wuthiekanun, V Aramrueung, P Khamnoi, P Thananchai, H Siriboon, S Chamnan, P Peacock, SJ Day, NPJ Thomson, NR Uttamapinant, C Wongpalee, SP Chewapreecha, C |
| author_facet | Pakdeerat, S Boonklang, P Angchagun, K Chomkatekaew, C Apichaidejudom, N Dokket, Y Faosap, A Wongsuwan, G Wuthiekanun, V Aramrueung, P Khamnoi, P Thananchai, H Siriboon, S Chamnan, P Peacock, SJ Day, NPJ Thomson, NR Uttamapinant, C Wongpalee, SP Chewapreecha, C |
| author_sort | Pakdeerat, S |
| collection | OXFORD |
| description | <p><strong>Background:</strong> Melioidosis is a neglected but often fatal tropical disease. The disease has broad clinical manifestations, which makes diagnosis challenging and time consuming. To improve diagnosis, we aimed to evaluate the performance of the CRISPR-Cas12a system (CRISPR-BP34) to detect <em>Burkholderia pseudomallei</em> DNA across clinical specimens from patients suspected to have melioidosis.</p>
<p><strong>Methods:</strong> We conducted a prospective, observational cohort study of adult patients (aged ≥18 years) with melioidosis at Sunpasitthiprasong Hospital, a tertiary care hospital in Thailand. Participants were eligible for inclusion if they had culture-confirmed <em>B pseudomallei</em> infection from any clinical samples. Data were collected from patient clinical records and follow-up telephone calls. Routine clinical samples (blood, urine, respiratory secretion, pus, and other body fluids) were collected for culture. We documented time taken for diagnosis, and mortality at day 28 of follow-up. We also performed CRISPR-BP34 detection on clinical specimens collected from 330 patients with suspected melioidosis and compared its performance with the current gold-standard culture-based method. Discordant results were validated by three independent qualitative PCR tests. This study is registered with the Thai Clinical Trial Registry, TCTR20190322003.</p>
<p><strong>Findings:</strong> Between Oct 1, 2019, and Dec 31, 2022, 876 patients with culture-confirmed melioidosis were admitted or referred to Sunpasitthiprasong Hospital, 433 of whom were alive at diagnosis and were enrolled in this study. Median time from sample collection to diagnosis by culture was 4·0 days (IQR 3·0–5·0) among all patients with known survival status at day 28, which resulted in delayed treatment. 199 (23%) of 876 patients died before diagnosis and 114 (26%) of 433 patients in follow-up were treated, but died within 28 days of admission. To test the CRISPR-BP34 assay, we enrolled and collected clinical samples from 114 patients with melioidosis and 216 patients without melioidosis between May 26 and Dec 31, 2022. Application of CRISPR-BP34 reduced the median sample-to-diagnosis time to 1·1 days (IQR 0·7–1·5) for blood samples, 2·3 h (IQR 2·3–2·4) for urine, and 3·3 h (3·1–3·4) for respiratory secretion, pus, and other body fluids. The overall sensitivity of CRISPR-BP34 was 93·0% (106 of 114 samples [95% CI 86·6–96·9]) compared with 66·7% (76 of 114 samples [57·2–75·2]) for culture. The overall specificity of CRISPR-BP34 was 96·8% (209 of 216 samples [95% CI 93·4–98·7]), compared with 100% (216 of 216 samples [98·3–100·0]) for culture.</p>
<p><strong>Interpretation:</strong> The sensitivity, specificity, speed, and window of clinical intervention offered by CRISPR-BP34 support its prospective use as a point-of-care diagnostic tool for melioidosis. Future development should be focused on scalability and cost reduction.</p> |
| first_indexed | 2024-04-23T08:25:34Z |
| format | Journal article |
| id | oxford-uuid:6213c65c-5310-4cd3-9695-4936148679f2 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-04-23T08:25:34Z |
| publishDate | 2024 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:6213c65c-5310-4cd3-9695-4936148679f22024-04-15T06:47:39ZBenchmarking CRISPR-BP34 for point-of-care melioidosis detection in low-income and middle-income countries: a molecular diagnostics studyJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:6213c65c-5310-4cd3-9695-4936148679f2EnglishSymplectic ElementsElsevier2024Pakdeerat, SBoonklang, PAngchagun, KChomkatekaew, CApichaidejudom, NDokket, YFaosap, AWongsuwan, GWuthiekanun, VAramrueung, PKhamnoi, PThananchai, HSiriboon, SChamnan, PPeacock, SJDay, NPJThomson, NRUttamapinant, CWongpalee, SPChewapreecha, C<p><strong>Background:</strong> Melioidosis is a neglected but often fatal tropical disease. The disease has broad clinical manifestations, which makes diagnosis challenging and time consuming. To improve diagnosis, we aimed to evaluate the performance of the CRISPR-Cas12a system (CRISPR-BP34) to detect <em>Burkholderia pseudomallei</em> DNA across clinical specimens from patients suspected to have melioidosis.</p> <p><strong>Methods:</strong> We conducted a prospective, observational cohort study of adult patients (aged ≥18 years) with melioidosis at Sunpasitthiprasong Hospital, a tertiary care hospital in Thailand. Participants were eligible for inclusion if they had culture-confirmed <em>B pseudomallei</em> infection from any clinical samples. Data were collected from patient clinical records and follow-up telephone calls. Routine clinical samples (blood, urine, respiratory secretion, pus, and other body fluids) were collected for culture. We documented time taken for diagnosis, and mortality at day 28 of follow-up. We also performed CRISPR-BP34 detection on clinical specimens collected from 330 patients with suspected melioidosis and compared its performance with the current gold-standard culture-based method. Discordant results were validated by three independent qualitative PCR tests. This study is registered with the Thai Clinical Trial Registry, TCTR20190322003.</p> <p><strong>Findings:</strong> Between Oct 1, 2019, and Dec 31, 2022, 876 patients with culture-confirmed melioidosis were admitted or referred to Sunpasitthiprasong Hospital, 433 of whom were alive at diagnosis and were enrolled in this study. Median time from sample collection to diagnosis by culture was 4·0 days (IQR 3·0–5·0) among all patients with known survival status at day 28, which resulted in delayed treatment. 199 (23%) of 876 patients died before diagnosis and 114 (26%) of 433 patients in follow-up were treated, but died within 28 days of admission. To test the CRISPR-BP34 assay, we enrolled and collected clinical samples from 114 patients with melioidosis and 216 patients without melioidosis between May 26 and Dec 31, 2022. Application of CRISPR-BP34 reduced the median sample-to-diagnosis time to 1·1 days (IQR 0·7–1·5) for blood samples, 2·3 h (IQR 2·3–2·4) for urine, and 3·3 h (3·1–3·4) for respiratory secretion, pus, and other body fluids. The overall sensitivity of CRISPR-BP34 was 93·0% (106 of 114 samples [95% CI 86·6–96·9]) compared with 66·7% (76 of 114 samples [57·2–75·2]) for culture. The overall specificity of CRISPR-BP34 was 96·8% (209 of 216 samples [95% CI 93·4–98·7]), compared with 100% (216 of 216 samples [98·3–100·0]) for culture.</p> <p><strong>Interpretation:</strong> The sensitivity, specificity, speed, and window of clinical intervention offered by CRISPR-BP34 support its prospective use as a point-of-care diagnostic tool for melioidosis. Future development should be focused on scalability and cost reduction.</p> |
| spellingShingle | Pakdeerat, S Boonklang, P Angchagun, K Chomkatekaew, C Apichaidejudom, N Dokket, Y Faosap, A Wongsuwan, G Wuthiekanun, V Aramrueung, P Khamnoi, P Thananchai, H Siriboon, S Chamnan, P Peacock, SJ Day, NPJ Thomson, NR Uttamapinant, C Wongpalee, SP Chewapreecha, C Benchmarking CRISPR-BP34 for point-of-care melioidosis detection in low-income and middle-income countries: a molecular diagnostics study |
| title | Benchmarking CRISPR-BP34 for point-of-care melioidosis detection in low-income and middle-income countries: a molecular diagnostics study |
| title_full | Benchmarking CRISPR-BP34 for point-of-care melioidosis detection in low-income and middle-income countries: a molecular diagnostics study |
| title_fullStr | Benchmarking CRISPR-BP34 for point-of-care melioidosis detection in low-income and middle-income countries: a molecular diagnostics study |
| title_full_unstemmed | Benchmarking CRISPR-BP34 for point-of-care melioidosis detection in low-income and middle-income countries: a molecular diagnostics study |
| title_short | Benchmarking CRISPR-BP34 for point-of-care melioidosis detection in low-income and middle-income countries: a molecular diagnostics study |
| title_sort | benchmarking crispr bp34 for point of care melioidosis detection in low income and middle income countries a molecular diagnostics study |
| work_keys_str_mv | AT pakdeerats benchmarkingcrisprbp34forpointofcaremelioidosisdetectioninlowincomeandmiddleincomecountriesamoleculardiagnosticsstudy AT boonklangp benchmarkingcrisprbp34forpointofcaremelioidosisdetectioninlowincomeandmiddleincomecountriesamoleculardiagnosticsstudy AT angchagunk benchmarkingcrisprbp34forpointofcaremelioidosisdetectioninlowincomeandmiddleincomecountriesamoleculardiagnosticsstudy AT chomkatekaewc benchmarkingcrisprbp34forpointofcaremelioidosisdetectioninlowincomeandmiddleincomecountriesamoleculardiagnosticsstudy AT apichaidejudomn benchmarkingcrisprbp34forpointofcaremelioidosisdetectioninlowincomeandmiddleincomecountriesamoleculardiagnosticsstudy AT dokkety benchmarkingcrisprbp34forpointofcaremelioidosisdetectioninlowincomeandmiddleincomecountriesamoleculardiagnosticsstudy AT faosapa benchmarkingcrisprbp34forpointofcaremelioidosisdetectioninlowincomeandmiddleincomecountriesamoleculardiagnosticsstudy AT wongsuwang benchmarkingcrisprbp34forpointofcaremelioidosisdetectioninlowincomeandmiddleincomecountriesamoleculardiagnosticsstudy AT wuthiekanunv benchmarkingcrisprbp34forpointofcaremelioidosisdetectioninlowincomeandmiddleincomecountriesamoleculardiagnosticsstudy AT aramrueungp benchmarkingcrisprbp34forpointofcaremelioidosisdetectioninlowincomeandmiddleincomecountriesamoleculardiagnosticsstudy AT khamnoip benchmarkingcrisprbp34forpointofcaremelioidosisdetectioninlowincomeandmiddleincomecountriesamoleculardiagnosticsstudy AT thananchaih benchmarkingcrisprbp34forpointofcaremelioidosisdetectioninlowincomeandmiddleincomecountriesamoleculardiagnosticsstudy AT siriboons benchmarkingcrisprbp34forpointofcaremelioidosisdetectioninlowincomeandmiddleincomecountriesamoleculardiagnosticsstudy AT chamnanp benchmarkingcrisprbp34forpointofcaremelioidosisdetectioninlowincomeandmiddleincomecountriesamoleculardiagnosticsstudy AT peacocksj benchmarkingcrisprbp34forpointofcaremelioidosisdetectioninlowincomeandmiddleincomecountriesamoleculardiagnosticsstudy AT daynpj benchmarkingcrisprbp34forpointofcaremelioidosisdetectioninlowincomeandmiddleincomecountriesamoleculardiagnosticsstudy AT thomsonnr benchmarkingcrisprbp34forpointofcaremelioidosisdetectioninlowincomeandmiddleincomecountriesamoleculardiagnosticsstudy AT uttamapinantc benchmarkingcrisprbp34forpointofcaremelioidosisdetectioninlowincomeandmiddleincomecountriesamoleculardiagnosticsstudy AT wongpaleesp benchmarkingcrisprbp34forpointofcaremelioidosisdetectioninlowincomeandmiddleincomecountriesamoleculardiagnosticsstudy AT chewapreechac benchmarkingcrisprbp34forpointofcaremelioidosisdetectioninlowincomeandmiddleincomecountriesamoleculardiagnosticsstudy |